SK95998A3 - Application of inhibitor for producing a medicament to prevent photoaging of undamaged human skin due to uvb irradiation exposure - Google Patents
Application of inhibitor for producing a medicament to prevent photoaging of undamaged human skin due to uvb irradiation exposure Download PDFInfo
- Publication number
- SK95998A3 SK95998A3 SK959-98A SK95998A SK95998A3 SK 95998 A3 SK95998 A3 SK 95998A3 SK 95998 A SK95998 A SK 95998A SK 95998 A3 SK95998 A3 SK 95998A3
- Authority
- SK
- Slovakia
- Prior art keywords
- inhibitor
- skin
- mmp
- uvb
- exposure
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 29
- 206010051246 Photodermatosis Diseases 0.000 title claims abstract description 24
- 230000008845 photoaging Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 26
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 7
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 7
- 230000004913 activation Effects 0.000 claims abstract description 5
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 102000030782 GTP binding Human genes 0.000 claims abstract description 4
- 108091000058 GTP-Binding Proteins 0.000 claims abstract description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims description 28
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 27
- 230000005855 radiation Effects 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 2
- 108010030545 N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide Proteins 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims description 2
- 229950001858 batimastat Drugs 0.000 claims description 2
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 claims description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims description 2
- 229950008959 marimastat Drugs 0.000 claims description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical group O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 claims 1
- 229940122091 Geranylgeranyltransferase inhibitor Drugs 0.000 claims 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000006698 induction Effects 0.000 description 22
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 16
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 16
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 13
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 13
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 12
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 12
- 206010015150 Erythema Diseases 0.000 description 12
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 12
- 229930002330 retinoic acid Natural products 0.000 description 12
- 229960001727 tretinoin Drugs 0.000 description 12
- 102100030416 Stromelysin-1 Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 6
- 229940124761 MMP inhibitor Drugs 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 101710108790 Stromelysin-1 Proteins 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000475 sunscreen effect Effects 0.000 description 5
- 239000000516 sunscreening agent Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000812 repeated exposure Toxicity 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100028848 Stromelysin-2 Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102000011068 Cdc42 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 101710108792 Stromelysin-2 Proteins 0.000 description 2
- 102100028847 Stromelysin-3 Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- ZGIGZINMAOQWLX-NCZFFCEISA-N 3,7,11-Trimethyl-2,6,10-dodecatrienyl acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(C)=O ZGIGZINMAOQWLX-NCZFFCEISA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010050892 BZA 5B Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- ZGIGZINMAOQWLX-UHFFFAOYSA-N Farnesyl acetate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOC(C)=O ZGIGZINMAOQWLX-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000039539 Fos family Human genes 0.000 description 1
- 108091067362 Fos family Proteins 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013404 Geranyltranstransferase Human genes 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108040006417 JUN kinase kinase activity proteins Proteins 0.000 description 1
- 102000039537 Jun family Human genes 0.000 description 1
- 108091067369 Jun family Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- -1 ethylhexylmethoxycinnamic acid amide Chemical compound 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940007703 farnesyl acetate Drugs 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Percussion Or Vibration Massage (AREA)
- Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/588,771 US5837224A (en) | 1996-01-19 | 1996-01-19 | Method of inhibiting photoaging of skin |
| PCT/US1997/000791 WO1997025969A1 (en) | 1996-01-19 | 1997-01-17 | Method of inhibiting photoaging of skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK95998A3 true SK95998A3 (en) | 1999-01-11 |
Family
ID=24355242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK959-98A SK95998A3 (en) | 1996-01-19 | 1997-01-17 | Application of inhibitor for producing a medicament to prevent photoaging of undamaged human skin due to uvb irradiation exposure |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5837224A (hu) |
| EP (1) | EP0883398A4 (hu) |
| JP (1) | JP3705820B2 (hu) |
| CN (1) | CN1086937C (hu) |
| AR (1) | AR005650A1 (hu) |
| BR (1) | BR9707018A (hu) |
| CA (1) | CA2241981C (hu) |
| CO (1) | CO4770951A1 (hu) |
| CZ (1) | CZ291530B6 (hu) |
| EE (1) | EE9800216A (hu) |
| HK (1) | HK1018885A1 (hu) |
| HU (1) | HUP9900655A3 (hu) |
| LT (1) | LT4515B (hu) |
| MY (1) | MY119711A (hu) |
| NO (1) | NO983019L (hu) |
| NZ (1) | NZ330860A (hu) |
| PL (1) | PL327827A1 (hu) |
| SI (1) | SI9720015A (hu) |
| SK (1) | SK95998A3 (hu) |
| TR (1) | TR199801376T2 (hu) |
| WO (1) | WO1997025969A1 (hu) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528483B2 (en) | 1995-06-07 | 2003-03-04 | André Beaulieu | Method of producing concentrated non-buffered solutions of fibronectin |
| TR199800990T2 (xx) * | 1995-12-08 | 1998-07-21 | Agouron Pharmaceuticals, Inc. | Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler. |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| WO1998036742A1 (en) * | 1997-02-25 | 1998-08-27 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
| US20050058709A1 (en) * | 1997-06-04 | 2005-03-17 | Fisher Gary J. | Methods for inhibiting photoaging of human skin using orally-administered agent |
| JP3973748B2 (ja) * | 1998-01-14 | 2007-09-12 | 花王株式会社 | 発毛抑制剤 |
| US6683069B1 (en) * | 1998-04-02 | 2004-01-27 | Regents Of The University Of Michigan | Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin |
| FR2777183B1 (fr) * | 1998-04-10 | 2001-03-02 | Oreal | Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant |
| FR2777186B1 (fr) * | 1998-04-10 | 2001-03-09 | Oreal | Utilisation d'au moins un hydroxystilbene dans une composition raffermissante |
| US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
| US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
| US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US6071955A (en) * | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
| WO2000051562A1 (en) * | 1999-03-03 | 2000-09-08 | Shiseido Company, Ltd. | Matrix metalloprotease inhibitor and utilization thereof |
| WO2000059900A1 (en) * | 1999-04-01 | 2000-10-12 | The Board Of Trustees Of The University Of Arkansas | P38mapk inhibitor and uses thereof |
| US7268148B2 (en) * | 1999-05-20 | 2007-09-11 | Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| US20040235950A1 (en) * | 1999-05-20 | 2004-11-25 | Voorhees John J. | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| CA2378829A1 (en) * | 1999-07-20 | 2001-01-25 | Merck & Co., Inc. | Sustained release drug dispersion delivery device |
| US6982284B1 (en) | 1999-09-10 | 2006-01-03 | Applied Genetics Incorporated Dermatics | Compositions and methods for modification of skin lipid content |
| DE19955349A1 (de) * | 1999-11-17 | 2001-08-02 | Switch Biotech Ag | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
| JP4074043B2 (ja) * | 2000-03-27 | 2008-04-09 | 株式会社資生堂 | 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法 |
| DE10020447A1 (de) * | 2000-03-31 | 2001-10-11 | Henkel Kgaa | Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie |
| US20020012641A1 (en) * | 2000-06-26 | 2002-01-31 | Voorhees John J. | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| WO2002019982A2 (en) * | 2000-06-29 | 2002-03-14 | Quick Med Technologies, Inc. | Cosmetic composition and method for reducing or preventing wrinkling |
| US20040185127A1 (en) * | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
| EP1296638A2 (en) | 2000-07-06 | 2003-04-02 | The Regents Of The University Of Michigan | UVA (>360-400) AND UVB (300-325) SPECIFIC SUNSCREENS |
| FR2811561B1 (fr) * | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
| FR2811563B1 (fr) * | 2000-07-13 | 2003-06-20 | Oreal | Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes |
| US20020119107A1 (en) * | 2000-12-18 | 2002-08-29 | James Varani | Method for protecting and restoring skin using selective MMP inhibitors |
| DE10102784A1 (de) * | 2001-01-22 | 2002-08-01 | Henkel Kgaa | Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
| JP2002277455A (ja) * | 2001-03-15 | 2002-09-25 | Shiseido Co Ltd | 皮膚老化因子検出組成物及び検出方法 |
| MXPA04008722A (es) | 2002-03-08 | 2005-07-13 | Eisai Co Ltd | Compuestos macrociclicos utiles como farmaceuticos. |
| US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
| WO2003090688A2 (en) * | 2002-04-24 | 2003-11-06 | Van Andel Research Institute | Enhancement of human epidermal melanogenesis |
| JP5122060B2 (ja) * | 2002-06-25 | 2013-01-16 | 株式会社 資生堂 | 抗老化剤 |
| US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
| US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
| US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
| CN101845009B (zh) | 2002-07-29 | 2012-10-03 | 卡达克斯药物公司 | 用于抑制和改善疾病的类胡萝卜素结构类似物 |
| US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
| US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
| US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
| US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
| US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
| US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
| US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
| US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
| US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
| US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
| US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
| EP1617777A4 (en) | 2003-04-10 | 2010-11-03 | Gentlewaves Llc | PHOTOMODULATION METHODS AND DEVICES FOR REGULATING CELL PROLIFERATION AND GENE EXPRESSION |
| WO2005011606A2 (en) | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
| FR2858932B1 (fr) * | 2003-08-22 | 2009-10-30 | Oreal | Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle |
| US20050058611A1 (en) * | 2003-08-22 | 2005-03-17 | L'oreal | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight |
| EP1730522A2 (en) * | 2004-03-29 | 2006-12-13 | Howard Murad | Methods for treating dermatological conditions in a patient |
| EP1750723A1 (en) * | 2004-04-14 | 2007-02-14 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| US20060265030A1 (en) * | 2004-11-12 | 2006-11-23 | Light Bioscience, Llc | System and method for photodynamic cell therapy |
| WO2006071456A2 (en) * | 2004-12-02 | 2006-07-06 | The University Of North Carolina At Chapel Hill | Inhibition of hsp27 phosphorylation for treatment of blistering disorders |
| WO2007064871A2 (en) * | 2005-12-02 | 2007-06-07 | Howard Murad | Diagnostic and treatment regimen for achieving body water homeostasis |
| US7642402B2 (en) * | 2005-12-20 | 2010-01-05 | Kao Corporation | Human photoaged skin model |
| US8771647B2 (en) * | 2005-12-20 | 2014-07-08 | Kao Corporation | Human photoaged skin model |
| WO2007134219A2 (en) * | 2006-05-11 | 2007-11-22 | Living Proof, Inc. | In situ polymerization for skin treatment |
| KR100879558B1 (ko) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | 디벤조파라디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제 |
| WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
| CN102014859B (zh) * | 2008-04-22 | 2015-05-20 | 法国国家科学研究中心 | 抑制黑素生成的新组合物及其应用 |
| US8609075B2 (en) | 2009-09-30 | 2013-12-17 | Shiseido Company, Ltd. | Heparanase activity inhibitor |
| CN102573819A (zh) | 2009-09-30 | 2012-07-11 | 株式会社资生堂 | 乙酰肝素酶活性抑制剂以及含有该乙酰肝素酶活性抑制剂的皱纹改善剂和药物组合物 |
| US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
| US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
| EP2934555B1 (en) | 2012-12-21 | 2021-09-22 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells |
| JP2015221768A (ja) * | 2014-05-23 | 2015-12-10 | 日本メナード化粧品株式会社 | 皮膚外用剤または内用剤 |
| JP2016216435A (ja) * | 2015-05-18 | 2016-12-22 | 共栄化学工業株式会社 | 評価方法 |
| JP6157659B1 (ja) * | 2016-02-10 | 2017-07-05 | イノレックス インベストメント コーポレイション | 紫外線誘発性脂質過酸化を低減する相乗的組成物、配合物及び関連の方法 |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| CN112263529A (zh) * | 2020-10-27 | 2021-01-26 | 圣菲之美（湖北）生物科技有限公司 | 一种抗衰老组合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877805A (en) * | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
| US4603146A (en) * | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
| US5019569A (en) * | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| EP0357646B1 (en) * | 1987-04-06 | 1995-03-22 | Daltex Medical Sciences, Inc. | Treatment of aged skin with oral 13-cis-retinoic acid |
| US4994491A (en) * | 1988-12-14 | 1991-02-19 | Molecular Design International | Dermal uses of trans-retinoids for the treatment of cancer |
| MY106263A (en) * | 1989-01-19 | 1995-04-29 | Ortho Pharma Corp | Method for the treatment or prevention of intrinsically aged skin with retinoids |
| US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
| US5051449A (en) * | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
| WO1993010755A1 (en) * | 1991-11-25 | 1993-06-10 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
| GR1002207B (en) * | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
| JPH10513452A (ja) * | 1995-02-03 | 1998-12-22 | コスメダーム・テクノロジーズ | 皮膚刺激を軽減するための製剤及び方法 |
| JP2002515851A (ja) * | 1995-06-08 | 2002-05-28 | ジヨンソン・アンド・ジヨンソン・コンシユーマー・カンパニーズ・インコーポレーテツド | 日光遮蔽組成物 |
| US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
-
1996
- 1996-01-19 US US08/588,771 patent/US5837224A/en not_active Expired - Lifetime
-
1997
- 1997-01-17 CZ CZ19982258A patent/CZ291530B6/cs not_active IP Right Cessation
- 1997-01-17 EE EE9800216A patent/EE9800216A/xx unknown
- 1997-01-17 WO PCT/US1997/000791 patent/WO1997025969A1/en active IP Right Grant
- 1997-01-17 CA CA002241981A patent/CA2241981C/en not_active Expired - Lifetime
- 1997-01-17 HU HU9900655A patent/HUP9900655A3/hu unknown
- 1997-01-17 BR BR9707018A patent/BR9707018A/pt not_active IP Right Cessation
- 1997-01-17 EP EP97903847A patent/EP0883398A4/en not_active Withdrawn
- 1997-01-17 MY MYPI97000167A patent/MY119711A/en unknown
- 1997-01-17 JP JP52622497A patent/JP3705820B2/ja not_active Expired - Fee Related
- 1997-01-17 AR ARP970100191A patent/AR005650A1/es unknown
- 1997-01-17 SI SI9720015A patent/SI9720015A/sl unknown
- 1997-01-17 CN CN97191735A patent/CN1086937C/zh not_active Expired - Fee Related
- 1997-01-17 SK SK959-98A patent/SK95998A3/sk unknown
- 1997-01-17 PL PL97327827A patent/PL327827A1/xx unknown
- 1997-01-17 NZ NZ330860A patent/NZ330860A/xx not_active IP Right Cessation
- 1997-01-17 CO CO97001933A patent/CO4770951A1/es unknown
- 1997-01-17 TR TR1998/01376T patent/TR199801376T2/xx unknown
-
1998
- 1998-06-29 NO NO983019A patent/NO983019L/no not_active Application Discontinuation
- 1998-07-09 LT LT98-091A patent/LT4515B/lt not_active IP Right Cessation
-
1999
- 1999-09-14 HK HK99103976A patent/HK1018885A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CO4770951A1 (es) | 1999-04-30 |
| CA2241981C (en) | 2002-03-19 |
| US5837224A (en) | 1998-11-17 |
| LT98091A (en) | 1999-02-25 |
| HUP9900655A1 (hu) | 1999-07-28 |
| CA2241981A1 (en) | 1997-07-24 |
| NO983019L (no) | 1998-08-19 |
| HK1018885A1 (en) | 2000-01-07 |
| AU1831797A (en) | 1997-08-11 |
| EP0883398A4 (en) | 1999-05-12 |
| AR005650A1 (es) | 1999-07-14 |
| JP3705820B2 (ja) | 2005-10-12 |
| EE9800216A (et) | 1999-04-15 |
| MY119711A (en) | 2005-07-29 |
| LT4515B (lt) | 1999-06-25 |
| JP2000503660A (ja) | 2000-03-28 |
| NO983019D0 (no) | 1998-06-29 |
| NZ330860A (en) | 1999-11-29 |
| AU701132B2 (en) | 1999-01-21 |
| BR9707018A (pt) | 1999-07-20 |
| SI9720015A (sl) | 1999-10-31 |
| CZ225898A3 (cs) | 1998-10-14 |
| WO1997025969A1 (en) | 1997-07-24 |
| HUP9900655A3 (en) | 2000-09-28 |
| EP0883398A1 (en) | 1998-12-16 |
| CN1086937C (zh) | 2002-07-03 |
| CN1211178A (zh) | 1999-03-17 |
| CZ291530B6 (cs) | 2003-03-12 |
| TR199801376T2 (xx) | 1998-10-21 |
| PL327827A1 (en) | 1999-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK95998A3 (en) | Application of inhibitor for producing a medicament to prevent photoaging of undamaged human skin due to uvb irradiation exposure | |
| CA2601462C (en) | Compositions and methods for inhibiting photoaging of skin | |
| AU737376B2 (en) | Methods and compositions for preventing and treating chronological aging in human skin | |
| RU2111745C1 (ru) | Жидкая композиция, предназначенная для местного применения | |
| Polte et al. | Involvement of lipid peroxidation and organic peroxides in UVA-induced matrix metalloproteinase-1 expression | |
| US20050058709A1 (en) | Methods for inhibiting photoaging of human skin using orally-administered agent | |
| Morimoio et al. | Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. | |
| AU701132C (en) | Method of inhibiting photoaging of skin | |
| KR20010042422A (ko) | 인간 피부에서의 콜라젠 합성의 ｕｖ-유도 억제를감소시키는 방법 및 그 용도의 조성물 | |
| AU2002301116B2 (en) | Compositions and Methods for Inhibiting Photoaging of Skin | |
| Alberts et al. | Developing topical prodrugs for skin cancer prevention | |
| MXPA99007883A (es) | Metodos y composiciones para prevernir y tratar el envejecimiento cronológico en la piel humana | |
| MXPA99011052A (en) | Compositions and methods for inhibiting photoaging of skin | |
| Riccardi | Reversal of photoaging of the skin by topical d-alpha tocopherol, ascorbic acid, and L-selenomethionine: A comparative analysis performed by light and transmission electron microscopy |